反应详情

N-(1-(tert-Butyldimethylsilyloxy)-2-methylpropan-2-yl)-2-(6-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (75 mg, 0.16 mmol) was added to a saturated solution of HCl (g) in dioxane (15 mL) at room temperature and stirred for 2 hours. The reaction mixture was filtered, the filter cake washed with 2 mL of methanol, then dried at 40° C. under reduced pressure to give N-(1-hydroxy-2-methylpropan-2-yl)-2-(6-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxamide (15 mg, 26.4%) as a yellow solid. MS: (M+H)+=365; 1H NMR (300 MHz, DMSO): δ 13.34 (s, 1H), 12.76 (s, 1H), 9.14 (s, 1H), 8.46 (d, 1H, J=7.8 Hz), 8.35 (s, 1H), 7.95 (s, 1H), 7.41 (s, 1H), 7.09 (d, 1H, J=8.4 Hz), 5.05 (t, 1H, J=5.7 Hz), 3.65 (d, 1H, J=5.7 Hz), 2.50 (s, 3H), 1.46 (s, 6H).

1. filtrationThe reaction mixture was filtered
2. washthe filter cake washed with 2 mL of methanol
3. customdried at 40° C. under reduced pressure